tradingkey.logo

Oruka Therapeutics Announces Ind Clearance For Everlast-A Phase 2A Trial Of Orka-001 In Psoriasis With Phase 1 Data To Be Presented At Eadv In September

ReutersJul 21, 2025 11:02 AM

- Oruka Therapeutics Inc ORKA.O:

  • ORUKA THERAPEUTICS ANNOUNCES IND CLEARANCE FOR EVERLAST-A PHASE 2A TRIAL OF ORKA-001 IN PSORIASIS WITH PHASE 1 DATA TO BE PRESENTED AT EADV IN SEPTEMBER

  • ORUKA THERAPEUTICS: IND CLEARED FOR EVERLAST-A PHASE 2A TRIAL OF ORKA-001 IN MODERATE-TO-SEVERE PSORIASIS, WITH INITIAL DATA EXPECTED 2H 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI